Becker's Healthcare June 14, 2024
The FDA is now advising manufacturers to develop the 2024-2025 COVID-19 vaccines using the KP.2 strain for the formula, the agency announced June 13.
The update comes just one week after an FDA committee voted unanimously June 5 on the 2024-2025 COVID-19 vaccine makeup, recommending it should be one that targets the monovalent JN.1-lineage.
Following the June 5 vote, the committee further discussed if a specific strain from that lineage should be considered for the new vaccines to target, which is what led to this slight change in direction for manufacturers.
KP.2 is part of the JN.1 lineage, but the specification to use the KP.2 strain resulted from current data, which shows that the current...
Today's Sponsors
Today's Sponsor